OST and MORES in Male Osteoporosis
OST and MORES
Performance of the Osteoporosis Self-Assessment Tool (OST) and Male Osteoporosis Risk Estimate Score (MORES) in Predicting Osteoporosis in Turkish Men
1 other identifier
observational
140
1 country
1
Brief Summary
The aim of this study is to compare the Male Osteoporosis Risk Score and the Osteoporosis Self-Assessment Tool with the gold standard DEXA in determining the risk of osteoporosis in the lumbar and femoral regions in male individuals in the Turkish population, and to investigate their sensitivity and specificity in the first stage of screening for the detection of male osteoporosis.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Feb 2026
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
February 4, 2026
CompletedStudy Start
First participant enrolled
February 4, 2026
CompletedFirst Posted
Study publicly available on registry
April 8, 2026
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 1, 2026
CompletedStudy Completion
Last participant's last visit for all outcomes
September 15, 2026
ExpectedApril 8, 2026
April 1, 2026
5 months
February 4, 2026
April 4, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (3)
Dual energy Xray Absorptiometry (DEXA)
DEXA measures bone mineral density (BMD; g/cm2) based on the scanned bone area. T and Z scores are used to interpret DEXA results. The T score indicates how many standard deviations below or above the average BMD measurements of a patient of the same gender and younger adults. The T score should be used for the diagnosis of osteoporosis in postmenopausal women and men over 50 years of age. The Z score indicates how many standard deviations below or above the average BMD measurements of the same gender and age. The Z score should be used for the diagnosis of osteoporosis in premenopausal women and men under 50 years of age. According to the World Health Organization's definition of bone mineral density: * A T score between -1 and -2.5 SD indicates osteopenia. * A T score below -2.5 SD indicates osteoporosis. * A T score below -2.5 SD accompanied by a fragility fracture(s) indicates severe osteoporosis. • A Z-score of -2.0 SD or lower is defined as "below the expected range for age,"
January 2021-January 2024
MORES
The Male Osteoporosis Risk Prediction Score uses age, weight, and history of chronic obstructive pulmonary disease (COPD) to classify the risk of osteoporosis in men aged 50 and older. Values of 6 or higher are the threshold for screening.
January 2021-January 2024
OST
The Osteoporosis Self-Assessment Tool (OSA) screening program is used to improve osteoporosis screening in patients. The main tool of this screening program is the OS, a risk formula based on age and weight. OS has proven to be a reliable screening tool for osteoporosis in both female and male populations. The OS score is calculated using the formula: OST Score = \[Weight (kg) - Age\] x 0.2. Osteoporosis risk: * High risk: -20 to -4 for women, -20 to -1 for men * Moderate risk: -4 to -1 for women, -1 to 4 for men * Low risk: -1 to 20 for women, -4 to 20 for men
January 2021-January 2024
Study Arms (1)
male osteoporosis group
Eligibility Criteria
This study will be conducted retrospectively at the Physical Medicine and Rehabilitation Clinic of Kayseri City Hospital between January 2024 and January 2025. This study will include male patients aged 50-75 who underwent osteoporosis screening with DEXA at the Kayseri City Hospital Physical Medicine and Rehabilitation outpatient clinics between January 2021 and January 2024.
You may not qualify if:
- Patients younger than 50 or older than 75 years of age
- Patients with secondary osteoporosis
- Female patients
- Patients with uncontrolled severe comorbid conditions
- Patients with a history of pathological fractures
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Kayseri City Education and Research Hospital
Kayseri, Kayseri, 38050, Turkey (Türkiye)
Study Officials
- PRINCIPAL INVESTIGATOR
Fatma Gül Ülkü Demir, MD
Kayseri City Hospital
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER GOV
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- MD
Study Record Dates
First Submitted
February 4, 2026
First Posted
April 8, 2026
Study Start
February 4, 2026
Primary Completion
July 1, 2026
Study Completion (Estimated)
September 15, 2026
Last Updated
April 8, 2026
Record last verified: 2026-04